1. Home
  2. BTZ vs CRVS Comparison

BTZ vs CRVS Comparison

Compare BTZ & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Credit Allocation Income Trust

BTZ

BlackRock Credit Allocation Income Trust

HOLD

Current Price

$10.18

Market Cap

998.6M

Sector

Finance

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$14.42

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTZ
CRVS
Founded
2006
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
998.6M
1.1B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
BTZ
CRVS
Price
$10.18
$14.42
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$30.17
AVG Volume (30 Days)
221.0K
1.5M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
9.40%
N/A
EPS Growth
N/A
48.04
EPS
1.41
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.70
$3.96
52 Week High
$11.18
$26.95

Technical Indicators

Market Signals
Indicator
BTZ
CRVS
Relative Strength Index (RSI) 50.71 51.59
Support Level $10.05 $14.24
Resistance Level $10.22 $16.66
Average True Range (ATR) 0.06 0.84
MACD -0.00 -0.14
Stochastic Oscillator 40.62 19.65

Price Performance

Historical Comparison
BTZ
CRVS

About BTZ BlackRock Credit Allocation Income Trust

Blackrock Credit Allocation Income Trust is a diversified, closed-end Trust engaged in providing investment advisory and risk management solutions. Its investment objective is to seek current income, current gains, and capital appreciation. The company invests under normal market conditions, at least 80% of its assets in credit-related securities, including, but not limited to, investment-grade corporate bonds, high-yields, bank loans, preferred securities or convertible bonds, or derivatives with economic characteristics similar to these credit-related securities.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: